Barry Byrne, MD, PhD, Powell Gene Therapy Center at the University of Florida, discusses gene therapy considerations for pediatric patients and how newborn screening can influence outcomes for patients with Duchenne muscular dystrophy (DMD).
Barry Byrne, MD, PhD
Advertisement
Barry Byrne, MD, PhD, pediatric cardiologist, director, Powell Gene Therapy Center, joined the University of Florida in 1997. Having taken on educational, clinical, and research roles alike, he is currently leading research efforts in the realm of rare diseases, particularly inherited muscular diseases.
Articles by Barry Byrne, MD, PhD
One of the major highlights of the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference is that invaluable networking opportunities can help clinicians elevate their own best practices.
Adeno-associated virus (AAV)–mediated gene therapy was one of the focal points of this year's Muscular Dystrophy Association conference. Here, Barry Byrne, MD, PhD, University of Florida, speaks to the novel development of AAV gene therapy and its mechanism of action.
Advertisement
Latest Updated Articles
Building Community and Advancing Care at MDA 2025March 24th 2025
Advertisement
Advertisement
Trending on AJMC
1
FDA Issues Complete Response Letter for Cingulate's Once-Daily ADHD Drug CTx-1301
2
Sudden Death in HFpEF Often Preceded by Clinical Decline
3
How Often Do Health Insurers Deny Doctor-Recommended Care?
4
New Data Support Pimicotinib as Durable for Rare Tenosynovial Giant Cell Tumor
5